initial public offerings (IPOs) trading on American exchanges

Thursday, April 28, 2022

Zymeworks (ZYME) : 5-year performance

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.
  • Sector(s): Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 455
  • incorporated in 2003 
  • HQ: Vancouver, Canada.

First day of trading Friday April 28, 2017
Vancouver, British Columbia-based biotherapeutics provider Zymeworks Inc has raised $58.5 million for its IPO after pricing its 4.5 million shares at $13 per share. The stock began trading April 28, 2017 on the New York Stock Exchange and on the Toronto Stock Exchange under the ticker symbol “ZYME";
Citigroup Global Markets Canada Inc., Barclays Capital Inc. and Wells Fargo Securities, LLC are the lead underwriters. Zymeworks'  pre-IPO backers include BDC Capital, Lumira Capital, CTI Life Sciences Fund, Fonds de solidarité FTQ, Perceptive Advisors, Teralys Capital, Northleaf Venture Catalyst Fund, Brace Pharma Capital and Merlin Nexus.

No comments:

Post a Comment